About: Irinotecan Hydrochloride     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Irinotecan Hydrochloride
rdfs:subClassOf
Has_Free_Acid_Or_Base_Form
Has_Target
Concept_In_Subset
Semantic_Type
  • Organic Chemical
  • Pharmacologic Substance
Preferred_Name
  • Irinotecan Hydrochloride
UMLS_CUI
  • C0594375
CAS_Registry
  • 136572-09-3
Accepted_Therapeutic_Use_For
  • State IVB Cervical cancer; Colorectal cancer; Esophageal cancer; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer
In_Clinical_Trial_For
  • Hepatocellular carcinoma; neuroblastoma; non-small cell lung cancer; pancreatic cancer; penile cancer; rhabdomyosarcoma; small bowel adenocarcinoma; small cell lung cancer; transitional cell cancer; unspecified solid tumors
  • Breast cancer; brain metastases; colorectal cancer; esophageal cancer; Ewings sarcoma; gastric or gastroesophageal adenocarcinoma; glioblastoma multiforme; gliomas
FDA_UNII_Code
  • 042LAQ1IIS
Contributing_Source
  • FDA
ALT_DEFINITION
  • A drug used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil. It is also being studied in the treatment of other types of cancer. Camptosar blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 41714
PDQ_Closed_Trial_Search_ID
  • 41714
Chemical_Formula
  • C33H38N4O6.HCl.3H2O
Legacy_Concept_Name
  • Irinotecan
FULL_SYN
  • irinotecan hydrochloridePTNCI-GLOSSCDR0000635811
  • CPT 11SYDTPNSC0616348
  • Irinotecan HydrochloridePTNCI
  • CPT 11PTNCI-GLOSSCDR0000044427
  • Camptothecin-11SYNCI
  • Camptothecin 11SYDTPNSC0616348
  • IRINOTECAN HYDROCHLORIDEPTFDA042LAQ1IIS
  • CPT-11CNNCI
  • CamptoFBNCI
  • CamptosarSYDTPNSC0616348
  • U-101440ECNNCI
  • CamptosarBRNCI
  • CamptosarPTNCI-GLOSSCDR0000635812
DEFINITION
  • The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.NCI
code
  • C1381
is someValuesFrom of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 26 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software